Guillain–Barré Syndrome Market Analysis, Epidemiology and Market Forecast to 2030
Guillain–Barré Syndrome (GBS) is a rare neurological disorder in which the body's immune system mistakenly attacks part of its peripheral nervous system—the network of nerves located outside of the brain and spinal cord. GBS can range from a very mild case with a brief weakness to nearly devastating paralysis, leaving the person unable to breathe independently.
Most people eventually recover from even the most severe cases of GBS. After recovery, some people will continue to have some degree of weakness.
Key Highlight of Guillain–Barré Syndrome Market As per the “National Institute of Health,” the Incidence of Guillain–Barré Syndrome is estimated to be 6–40 cases per 1 million people. As per the “National Institute of Health”, AMAN and AMSAN together account for 30–50 % of cases in Asian countries and Latin America but only 3–5 % of cases in North America and Europe. AIDP is the most frequent form of Guillain–Barré Syndrome (accounting for around 90% of cases), and thus the term GBS, in general, is synonymous with AIDP in Western countries.
For more details on Guillain–Barré Syndrome Market visit:
https://www.delveinsight.com/report-store/guillain-barre-syndrome-gbs-market
